This Oxford style roundtable debate will allow for participants to discuss and decide where they stand on key questions regularly raised on the role of pharmaceutical expenditure in the sustainability of healthcare systems across the EU. Whilst some argue that the rise of healthcare expenditure is linked to medicines and pharmaceutical innovations, others are now demonstrating that the net proportion of healthcare expenditure spent on medicines is actually decreasing. What side are you on?
The debate will start with the presentation by Jaime Espin, Professor at the Andalusian School of Public Health and lead author of the report on “Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates”, published in 2018.
The motion “Medicines are not a risk for health systems” will be supported by pro and con arguments.
During the debate, participants will be given a chance to have their say and challenge points that have been made by the speakers in favour or against the motion. The discussion will begin with participants casting a pre-debate vote on the motion that is either for, against or undecided. Each speaker will present a brief opening statement in favour and against the motion. The moderator will then open the floor to the room, encouraging debate and inter-panel challenges. Results are determined by a second vote at the end of the debate for comparison against the first.
This event is part of Friends of Europe’s Health and Wellbeing programme, which focuses on how the obstacles of vested interests and short-term political thinking can be overcome in the difficult transition to new healthcare models and systems – and how these new systems can be financed.
Should you not be able to view the gallery, please click here.
- Event summary
- Event report
- "Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates" by Jaime Espin, Professor at the Andalusian School of Public Health
Welcome and registration of participants
This Oxford style roundtable debate will respond to the motion “Medicine prices are not a risk for healthcare systems”.
Following a presentation by Jaime Espin, Professor at the Andalusian School of Public Health and lead author of the report on “Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates”, published in 2018, the motion will be supported by pro and con arguments substantiated by expertise opinion on the current state of healthcare in Europe.
The sustainability of healthcare systems across the European Union is under increasing pressure and scrutiny by taxpayers, and sources such as OECD data suggest that healthcare expenditure is rising with an expected growth rate of around 3% by 2030. While pharmaceutical innovations have the potential to improve patients’ life expectancy and quality of life, they also pose challenges to public health systems, including financial stability, post-market surveillance as well as patient access and affordability. However, publicly available data and related forecasts on pharmaceuticals do not paint a comprehensive picture of the situation: new analysis shows that pharmaceutical net expenditure is expected to grow at a sustainable rate of 1.5%. This suggests that the proportion of healthcare expenditure spent on medicines is actually decreasing.
- What would pharmaceutical forecasts look like if they were adjusted to rebates and discounts on drug prices that national healthcare systems negotiate with the industry?
- How would such these discounts and rebates influence healthcare systems, the pharmaceutical industry and health technology assessment agencies?
- What can societies gain from investing in new pharmaceuticals?
Participants in the room will be encouraged to actively engage and decide where they stand on the role of pharmaceutical expenditure in the sustainability of healthcare systems across the EU.
Structure of the debate:
Welcome by moderator Tamsin Rose and first vote
Presentation of the motion by Jaime Espin, Professor at the Andalusian School of Public Health
Comments in favour of the motion by Thomas Allvin, Executive Director for Strategy and Healthcare systems at European Federation of Pharmaceutical Industries Association (EFPIA)
Comments against the motion by Jo de Cock, General Administrator of the Belgian National Institute for Health and Disability Insurance (INAMI)
Question and answers with speakers and audience
Final comments in favour and against the motion by Thomas Allvin and Jo de Cock
Closing remarks by moderator and final vote
Kick-starters and participants include:
Nicola Bedlington, Secretary General of the European Patient’s Forum
Sylvain Giraud, Head of Unit for Performance of National Health Systems at the European Commission Directorate-General for Health and Food Safety
Adrian Van den Hoven, Director General, Medicines for Europe
Lieve Wierinck, Member of the European Parliament Committee on Industry, Research and Energy
Wendy Yared, Director of the Assicuation of European Cancer Leagues (ECL)
End of debate
This event is by invitation only. For more information, please contact Sarah Bentz.
Sarah Bentz, Programme Manager
Tel.: +32 2 893 98 23
Our events include photos, audio and video recording that we might use for promotional purposes. By registering, you give your permission to use your image. Should you have any questions, please contact us.